Akero Therapeutics, Inc.
SEC CIK 1744659 · AKRO · last insider filing 2025-12-09
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Harrison Seth Loring | Director | filed 2019 - 2025 |
| Iwicki Mark T | Director | filed 2019 - 2025 |
| Henderson Jane | Director | filed 2019 - 2025 |
| Graham G. Walmsley | Director | filed 2019 - 2025 |
| Cheng Andrew | Director · President and CEO | filed 2019 - 2025 |
| Heyman Tomas J. | Director | filed 2020 - 2025 |
| Xu Yuan | Director | filed 2021 - 2025 |
| Judy Chou | Director | filed 2021 - 2025 |
| Bitterman Kevin | Director | filed 2019 - 2021 |
| Royston Aaron | Director | filed 2019 - 2019 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Gangloff Scott A. | Chief Technology Officer | filed 2024 - 2025 |
| White William Richard | EVP, Chief Financial Officer | filed 2019 - 2025 |
| Yale Catriona | Chief Development Officer | filed 2019 - 2025 |
| Rolph Timothy | Chief Scientific Officer | filed 2019 - 2025 |
| Young Jonathan | EVP, Chief Operating Officer | filed 2019 - 2025 |
| Lamy Patrick | Senior VP, Commercial Strategy | filed 2023 - 2025 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.